Association of warfarin therapy duration after bioprosthetic aortic valve replacement with risk of mortality, thromboembolic complications, and bleeding

JAMA

Volumn 308, Issue 20, 2012, Pages 2118-2125

  Mérie, Charlotte ^a   Køber, Lars ^b   Skov Olsen, Peter ^b   Andersson, Charlotte ^a   Gislason, Gunnar ^a   Skov Jensen, Jan ^a   Torp Pedersen, Christian ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ADULT; AGED; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART VALVE BIOPROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL TIME; THROMBOEMBOLISM; TREATMENT DURATION;

EID: 84869792164     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.54506     Document Type: Article

References (27)

1. Bonow RO, Carabello BA, Chatterjee K, et al American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol. 2008;52(13):e1-e142.
2. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease: native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3)(suppl):457S-482S. (Pubitemid 39297961)
3. Vahanian A, Baumgartner H, Bax J, et al Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28(2):230-268. (Pubitemid 46276943)
4. Heras M, Chesebro JH, Fuster V, et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol. 1995;25(5):1111-1119.
5. Krarup LH, Boysen G, Janjua H, Prescott E, Truelsen T. Validity of stroke diagnoses in a National Register of patients. Neuroepidemiology. 2007;28(3):150-154. (Pubitemid 47344336)
6. Madsen M, Davidsen M, Rasmussen S, Abildstrom SZ, Osler M. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol. 2003;56(2):124-130. (Pubitemid 36315938)
7. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433-1441.
8. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull. 1997;44(4):445-448. (Pubitemid 27382061)
9. Orszulak TA, Schaff HV, Mullany CJ, et al. Risk of thromboembolism with the aortic Carpentier-Edwards bioprosthesis. Ann Thorac Surg. 1995;59(2):462-468.
10. Tiede DJ, Nishimura RA, Gastineau DA, Mullany CJ, Orszulak TA, Schaff HV. Modern management of prosthetic valve anticoagulation. Mayo Clin Proc. 1998;73(7):665-680. (Pubitemid 28307726)
11. Whitley WS, Glas KE. An argument for routine ultrasound screening of the thoracic aorta in the cardiac surgery population. Semin Cardiothorac Vasc Anesth. 2008;12(4):290-297.
12. Sundt TM, Zehr KJ, Dearani JA, et al. Is early anticoagulation with warfarin necessary after bioprosthetic aortic valve replacement? J Thorac Cardiovasc Surg. 2005;129(5):1024-1031. (Pubitemid 40631422)
13. Mistiaen W, Van Cauwelaert P, Muylaert P, Sys SU, Harrisson F, Bortier H. Thromboembolic events after aortic valve replacement in elderly patients with a Carpentier-Edwards Perimount pericardial bioprosthesis. J Thorac Cardiovasc Surg. 2004;127(4):1166-1170. (Pubitemid 38451953)
14. ElBardissi AW, DiBardino DJ, Chen FY, Yamashita MH, Cohn LH. Is early antithrombotic therapy necessary in patients with bioprosthetic aortic valves in normal sinus rhythm? J Thorac Cardiovasc Surg. 2010;139(5):1137-1145.
15. Salem DN, O'Gara PT, Madias C, Pauker SG; American College of Chest Physicians. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6)(suppl):593S-629S. (Pubitemid 351892973)
16. Gherli T, Colli A, Fragnito C, et al. Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study. Circulation. 2004;110(5):496-500. (Pubitemid 39036177)
17. Aramendi JL, Agredo J, Llorente A, Larrarte C, Pijoan J. Prevention of thromboembolism with ticlopidine shortly after valve repair or replacement with a bioprosthesis. J Heart Valve Dis. 1998;7(6):610-614. (Pubitemid 28547121)
18. Nowell J, Wilton E, Markus H, Jahangiri M. Antithrombotic therapy following bioprosthetic aortic valve replacement. Eur J Cardiothorac Surg. 2007;31(4):578-585. (Pubitemid 46402975)
19. Colli A, Verhoye JP, Heijmen R, et al ACTION Registry Investigators. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results. Eur J Cardiothorac Surg. 2008;33(4):531-536.
20. Bucerius J, Gummert JF, Borger MA, et al. Stroke after cardiac surgery: a risk factor analysis of 16,184 consecutive adult patients. Ann Thorac Surg. 2003;75(2):472-478. (Pubitemid 36184491)
21. Higgins J, Jamieson WR, Benhameid O, et al. Influence of patient gender on mortality after aortic valve replacement for aortic stenosis. J Thorac Cardiovasc Surg. 2011;142(3):595-601.
22. Brown ML, Schaff HV, Lahr BD, et al. Aortic valve replacement in patients aged 50 to 70 years: improved outcome with mechanical versus biologic prostheses. J Thorac Cardiovasc Surg. 2008;135(4):878-884.
23. Kolh P, Kerzmann A, Honore C, Comte L, Limet R. Aortic valve surgery in octogenarians: predictive factors for operative and long-term results. Eur J Cardiothorac Surg. 2007;31(4):600-606. (Pubitemid 46400496)
24. Thourani VH, Keeling WB, Sarin EL, et al. Impact of preoperative renal dysfunction on long-term survival for patients undergoing aortic valve replacement. Ann Thorac Surg. 2011;91(6):1798-1806.
25. Melby SJ, Zierer A, Kaiser SP, et al. Aortic valve replacement in octogenarians: risk factors for earlyandlate mortality. Ann Thorac Surg. 2007;83(5):1651-1656.
26. Tjang YS, van Hees Y, Körfer R, Grobbee DE, van der Heijden GJ. Predictors of mortality after aortic valve replacement. Eur J Cardiothorac Surg. 2007;32(3):469-474. (Pubitemid 47223739)
27. Brennan JM, Alexander KP, Wallace A, et al. Patterns of anticoagulation following bioprosthetic valve implantation: observations from ANSWER. J Heart Valve Dis. 2012;21(1):78-87.